AGM/EGMJun 12, 2026, 04:17 PM
BioCryst Stockholders Approve Incentive Plan, Adding 7M Shares
AI Summary
BioCryst Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where several key proposals were approved. Stockholders voted to amend and restate the Stock Incentive Plan, increasing the number of shares available for issuance by 7,000,000. Additionally, three directors were elected, the appointment of Ernst & Young LLP as independent accountants for 2026 was ratified, and a non-binding advisory vote approved the company's executive compensation.
Key Highlights
- Stockholders approved the amended and restated Stock Incentive Plan, increasing shares by 7,000,000.
- The Incentive Plan Proposal was approved with 119,765,948 FOR votes.
- Theresa M. Heggie was elected director with 176,939,696 FOR votes.
- Amy E. McKee, M.D. was elected director with 178,820,838 FOR votes.
- Jon P. Stonehouse was elected director with 173,944,412 FOR votes.
- Ernst & Young LLP was ratified as independent registered public accountants for 2026 with 210,304,554 FOR votes.
- The non-binding, advisory resolution regarding executive compensation was approved with 126,098,528 FOR votes.
Price Impact
More from BCRX